VivaDiag SARS-CoV-2 Ag Rapid Test

VivaDiag SARS-CoV-2 Ag Fast Check relies on immunoassay know-how for the speedy, qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in human oropharyngeal or nasopharyngeal swab specimens. The check generates a end result inside 15 minutes figuring out individuals contaminated with COVID-19 rapidly serving to to comprise the unfold of the virus.

The package comprises all gadgets required together with swab, extraction tube, extraction resolution and lateral circulation check system. No specialised gear or personnel is required to make use of this check. The assessments may be carried out in any setting at any time by educated personnel, i.e for skilled use solely

This lateral circulation Covid-19 Fast Antigen Check Equipment is for easy for educated personnel to manage delivering correct outcomes quickly utilizing the oropharyngeal or nasopharyngeal swab specimen.

With the specimen collected insert the swab into the extraction tube stuffed with extraction resolution. Having eliminated a testing system from the sealed pouch apply three drops of the answer and wait 15 minutes earlier than studying the check, a optimistic or detrimental result’s clearly indicated.

This Covid-19 Fast Antigen Check Equipment has an general accuracy of 98.79%, a specificity of 99.12% and a sensitivity of 90.90% offering full assurance of quick, correct, dependable outcomes.

These assessments must be used as a part of a totally built-in COVID-19 technique, serving to determine these contaminated to cut back the unfold of the virus. VivaDiag™ SARS-CoV-2 Ag Fast Check has ONLY been designed to behave as a supplementary check for suspected instances of detrimental coronavirus nucleic acid detection or along with nucleic acid detection within the analysis of suspected instances. Outcomes from nucleocapsid protein antigen testing shouldn’t be used as the only real foundation to diagnose or exclude SARS-CoV-2 (COVID-19) an infection or to tell an infection standing.

Precept and meant use

Immupass VivaDiag SARS-CoV-2 Ag Fast Check is meant for medical laboratories and healthcare skilled use just for point-of-care testing. Not for at-home testing.

Immupass VivaDiag™ SARS-CoV-2 Ag Fast Check relies on immunoassay know-how. Every check system has one line of anti-SARS coronavirus monoclonal antibody on the detection line (T line) and one line of anti-mouse IgG polyclonal antibody on the standard management line (C line).

When extracted specimen is added to the specimen properly, it should react with the labeled antibody to type a posh, the combination then migrates by way of the membrane by capillary motion and interacts with the coated anti-SARS coronavirus monoclonal antibody on the detection line. If the specimen comprises SARS-CoV-2 antigen, the detection line will seem purplish-red indicating the SARS-CoV-2 antigen is optimistic. In any other case, the check end result shall be detrimental. The check system additionally comprises a top quality management line C which ought to seem purplish-red for all legitimate assessments. If the standard management line C doesn’t seem, the check end result shall be invalid even when the detection line seems.

Composition

Every check package comprises: 25 check gadgets, 25 extraction tubes (prefilled with extraction resolution 300 μL / tube), filtered nozzles, 1 tube stand, 25 sterile swabs and 1 bundle insert.

Supplies required however could not supplied: timer.

Specification

SARS-CoV-2 Rapid Antigen Test Nasal
9901-NCOV-03G	Roche Diagnostics	25 Tests/Kit	EUR 112.8
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke

Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva)
IOV87952	INVBIO	20T/kit	EUR 46.8
Description: Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva) is an in vitro diagnostic test for the qualitative detection of novel coronavirus antigens in human saliva, using the rapid immunochromatographic method. The identification is based on the monoclonal antibodies specific for the novel coronvirus antigen. It will provide information for clinical doctors to prescribe correct medications.

3CL Protease (SARS-CoV-1 / SARS-CoV-2) Substrate
79952-2	BPS Bioscience	10 mg	EUR 3460
Description: Sensitive internally quenched fluorogenic (FRET) substrate for SARS main protease with a Km value of 17 µM and a kcat value of 1.9 s»¹.

SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag
E80027	EpiGentek	EUR 635.80 EUR 4087.60	1 ml 100 ul

Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial
E80028	EpiGentek	EUR 388.30 EUR 860.20	20 ul 100 ul

Spike (SARS-CoV-2) Lentivirus
78010-2	BPS Bioscience	500 µl x 2	EUR 2095
Description: Cell entry of SARS-CoV-2 depends on the binding of viral spike protein to cellular receptor ACE2. The SARS-CoV-2 Spike Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. The particles contain the full length SARS-CoV-2 spike gene (QHD43416.1) driven by an EF1a promoter._x000D_

3CL Protease (SARS-CoV-2)
100823-2	BPS Bioscience	500 µg_x000D_	EUR 3360
Description: Severe acute respiratory Coronavirus 2 3C-like protease (SARS-CoV-2 3CL Protease), GenBank Accession No. YP_009725301, a.a. 1-306(full length), expressed in an E. coli expression system, MW=34 kDa.

Dynamiker Monkeypox Virus Ag Rapid Test
DNK-2114-1	Dynamiker Biotechnology	20 tests	EUR 702
Description: The product is a lateral flow chromatographic immunoassay for the qualitative detection of monkeypox virus antigen in human whole blood, serum, plasma or rash exuudate. The kit is intended for professional use only.

SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag
E80024	EpiGentek	EUR 635.80 EUR 4995.10	100 ul 1 ml

SARS-CoV-2 Spike S1 RBD Protein, Mouse Fc-fusion
E80026	EpiGentek	EUR 588.50 EUR 823.90	20 ul 50 ul

SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag
E80021	EpiGentek	EUR 635.80 EUR 4276.80	100 ul 1 ml

SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-His-tag
E80023	EpiGentek	EUR 635.80 EUR 3934.70	100 ul 1 ml

PLPro, His-tag (SARS-CoV-2)
100735-2	BPS Bioscience	1 mg	EUR 3000
Description: SARS-Cov-2 papain-like protease (PLPro), part of a large replicase polyprotein 1ab (E1564-Y1882), GenBank Accession No. QHD43415, with a N-terminal His-tag, expressed in an E. coli expression system. MW=38 kDa.

NSP10/NSP16 Complex (SARS-CoV-2)
100747-2	BPS Bioscience	1 mg	EUR 2500
Description: Complex of SARS-CoV-2 nonstructural protein 10 (NSP10), GenBank Accession No. YP_009725306.1, a.a. 1-139(full length), with N-terminal FLAG-tag, MW=16 kDa and SARS-CoV-2 nonstructural protein 16 (NSP16), Genbank Accession No. YP_009725311, a.a. 1-298(full length), with N-terminal His-tag, MW=34 kDa, co-expressed in a HEK293 cell expression system.

NSP7, His-tag (SARS-CoV-2)
100829-2	BPS Bioscience	1 mg	EUR 2600
Description: SARS-CoV-2 nonstructural protein 7 (NSP7), Genbank Accession No.: YP_009742614, a.a. 1-84(full length), with C-terminal His-tag, expressed in an E. coli expression system. MW= 10 kDa.

NSP8, His-tag (SARS-CoV-2)
100830-2	BPS Bioscience	1 mg	EUR 2730
Description: SARS-CoV-2 nonstructural protein 8 (NSP8), Genbank Accession No.: YP 009725304.1, a.a. 1-198(full length), with C-terminal His-tag, expressed in an E. coli expression system. MW= 23 kDa.

Anti-Nucleocapsid Antibody (SARS-CoV-2 )
100861-2	BPS Bioscience	100 µg	EUR 420
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Nucleocapsid (N) protein.

ORF9b, GST-Tag (SARS-CoV-2)
100962-2	BPS Bioscience	1 mg	EUR 2720
Description: Recombinant ORF9b, full length, encompassing amino acids 1-97(end). This recombinant protein corresponds to SARS-CoV-2 accessory protein ORF9b. It was expressed in E.coli and contains an N-terminal GST tag and a prescission protease cleavage site. The recombinant protein is >90% pure following GST affinity purification.

SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag
E80020	EpiGentek	EUR 635.80 EUR 4276.80	100 ul 1 ml

SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag
E80022	EpiGentek	EUR 635.80 EUR 4276.80	100 ul 1 ml

SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag
E80025	EpiGentek	EUR 635.80 EUR 3934.70	100 ul 1 ml

3CL Protease (SARS-CoV-2) Assay Kit
79955-2	BPS Bioscience	384 rxns.	EUR 1265
Description: The 3CL Protease Assay Kit is designed to measure 3CL Protease activity for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps. 3CL inhibitor GC376 is also included as an inhibitor control.

Spike S1, Fc fusion (SARS-CoV-2)
100688-2	BPS Bioscience	50 µg	EUR 505
Description: SARS-CoV-2 2019-nCoV Spike protein S1, also known as SARS-CoV s1 and coronavirus spike S1, GenBank Accession No. QHD43416.1, a.a. 16-685, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW= 160 kDa.

Anti-Spike S1 Antibody (SARS-CoV-2)
100715-2	BPS Bioscience	100 µg	EUR 440
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Spike RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus.

Spike S2, Fc-Tag (SARS-CoV-2)
100895-2	BPS Bioscience	500 µg_x000D_	EUR 1815
Description: SARS-CoV-2 Spike protein S2 subunit, also known as 2019-nCoV Spike S2, GenBank Accession No. MN908947, a.a. 686-1212, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=130 kDa.